NCT06207370Phase 2Recruiting

Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis

Study sponsor: 60 Degrees Pharmaceuticals LLC

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-03-01Estimated

Enrollment · participants33Estimated

Source updated2025-11-21Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2025-11-21 · 1 field changed

Primary completion date

Recorded edit

− Previous value

2025-03-01

+ Updated value

2027-03-01

Check registry source

Study details

Conditions studied

Babesiosis

Treatments or interventions studied

TafenoquineDrug

Primary outcomes · main study measures

Read the study measures

measure: Time to sustained clinical resolution; description: Time to sustained clinical resolution of all the following symptoms of babesiosis: sweats, joint aches, cough, loss of appetite, muscle aches, headache, chills or shivering, feeling hot or feverish, nausea, fatigue (low energy or tiredness), and vomiting. The time to achieve sustained clinical resolution will be the date when patients first self-report a 7-day period without these symptoms relative to the start of tafenoquine or placebo treatment.; timeFrame: Day 1 to 90

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history